• Hausa Edition
  • Podcast
  • Conferences
  • LeVogue Magazine
  • Business News
  • Print Advert Rates
  • Online Advert Rates
  • Contact Us
Saturday, June 7, 2025
Leadership Newspapers
Read in Hausa
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Health
  • Entertainment
  • Opinion
    • Editorial
  • Columns
  • Football
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Health
  • Entertainment
  • Opinion
    • Editorial
  • Columns
  • Football
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us
No Result
View All Result
Leadership Newspapers
No Result
View All Result

New HIV Prevention Injection Safe, Effective – Study

by Royal Ibeh
12 months ago
in News
HIV Prevention
Share on WhatsAppShare on FacebookShare on XTelegram

One of the Human Immunodeficiency Virus (HIV) prevention Injections, Lenacapavir,  that was being studied in the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda, is safe and highly effective against the virus.

Advertisement

The study enrolled over 5,300 cisgender adolescent girls and young women ages 16-26 in South Africa and Uganda. The study evaluated injectable Lenacapavir for PrEP and daily oral emtricitabine/tenofovir alafenamide (F/TAF) for PrEP.

A companion trial, PURPOSE 2, is underway in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the US, testing twice-yearly Lenacapavir for PrEP among cisgender men who have sex with men, transgender women, transgender men, and gender non-binary people. Results from PURPOSE 2 are expected by early 2025.

Additional studies in critical populations, including PURPOSE 3 among cisgender women in the US and PURPOSE 4 among people who use injection drugs, are also underway, and it will be imperative to understand how today’s results influence these trials. A schematic of the suite of studies is here.

An independent data and safety monitoring board (DSMB), at a scheduled review of the trial data, found the regimen to be safe and highly effective, with no infections seen among trial participants who received injectable Lenacapavir.

RELATED

Pacquiao, PL India, Others Celebrate Ronaldo At 39

Ronaldo Turns Down Offers To Play At Club World Cup

54 seconds ago
Tinubu Mourns Boxing Legend Nwankpa

Tinubu Mourns Boxing Legend Nwankpa

2 minutes ago

AVAC’s executive director, Mitchell Warren, in a press statement made available to LEADERSHIP, said, “This is one of the most important results we’ve seen to date in an HIV prevention study. Adding additional HIV prevention options means more people may find an option that is right for them. Beyond expanded choice, a twice-yearly injection has the potential to transform the way we deliver HIV prevention to people who need and want it most – from an easier-to-follow regimen for individuals to a decreased burden on healthcare systems that are stretched to the limit.”

Nandisile Sikwana, the regional stakeholder engagement manager for AVAC and a PURPOSE 1 Global Community Advisory Group member, said, “We are incredibly excited about this result, especially about what it can mean for women in Africa.

“We applaud Gilead’s commitment to good participatory practice in this and the other PURPOSE studies. While we wait for full data from the study, including adherence data of oral F/TAF, it is imperative that planning for the rollout of Lenacapavir be accelerated. We know that even with the most ambitious timeline, it will take time for Lenacapavir to be rolled out,” he said.

Gilead’s plans for submission to regulatory agencies and future access, including the US Food and Drug Administration (FDA), are unclear. But the results reported today make this urgent.

Warren added, “We expect to see a timeline that considers a full analysis of PURPOSE 1 data and the coming data from PURPOSE 2 from Gilead as soon as possible, and we urge regulatory agencies to prepare for a fast-track regulatory review. We also call on WHO to be prepared to quickly include lLenacapavir, if approved by regulatory agencies, in HIV prevention guidelines. There is no time to waste if we are to translate these exciting clinical trial results into actual public health impact and expand the toolbox of HIV prevention choices.”

“We now know that Lenacapivir for PrEP is safe and highly effective among women. Even as we await the results of the trial among other essential populations and for regulatory submission and review, there is urgent work to be done now by communities, policymakers, funders and program implementers to design and build HIV prevention programs and prepare health systems to deliver the growing array of biomedical PrEP options, including the addition of twice-yearly injectable Lenacapavir. The full range of PrEP products – including oral PrEP – must be made feasible choices for all people who need and want HIV prevention options.” Sikwana added.

Lessons learned from rollout of daily oral PrEP, and more recently, the dapivirine vaginal ring and injectable cabotegravir, can help speed regulatory approval and guideline development in key countries, design of effective programmes, and community understanding of and acceptance of lenacapavir for PrEP.

 

“AVAC and a cadre of international partners have been working together to plan for successful, accelerated introduction of lenacapavir. Since oral PrEP was first shown to be safe and effective 14 years ago, the global health community has failed to deliver PrEP at scale and with equity – and we have not seen the impact that we need. The lessons from the past are clear, and we now must act on them and move with speed, scale and urgency. There can be no excuses and no delays.

 

“We look forward to working with civil society partners, Gilead, international donors, normative agencies and national governments to ensure that this groundbreaking HIV prevention option is made available as quickly as possible and that we don’t squander this opportunity to drive down new HIV infections,” Warren added.

 

 


We’ve got the edge. Get real-time reports, breaking scoops, and exclusive angles delivered straight to your phone. Don’t settle for stale news. Join LEADERSHIP NEWS on WhatsApp for 24/7 updates →

Join Our WhatsApp Channel

START EARNING US DOLLARS as a Nigerian ($35,000) monthly. Companies are sacking their workers due to AI (artificial intelligence), business owners are in panic mode. Only the smart will make it. Click here


Tags: HIV
SendShareTweetShare
Previous Post

Cholera Kills 21 In Lagos, Cases Hit 401

Next Post

2 Weeks After, Niger Miners Still Trapped

Royal Ibeh

Royal Ibeh

You May Like

Pacquiao, PL India, Others Celebrate Ronaldo At 39
News

Ronaldo Turns Down Offers To Play At Club World Cup

2025/06/07
Tinubu Mourns Boxing Legend Nwankpa
News

Tinubu Mourns Boxing Legend Nwankpa

2025/06/07
NAF Denies Kaduna Airstrike, Urges Media to Verify Reports
News

PICTORIAL: NAF Airstrikes Destroy Terrorists’ Hideouts, Foil Eid Attack In Borno

2025/06/07
Ireland Eases Visa Rules For International Workers
News

Ireland Deports 35 Nigerians Over Immigration Rule Violations

2025/06/07
Bitget Hosts Blockchain Education Day To Foster Web3 Awareness Growth
Business

Bitget Hosts Blockchain Education Day To Foster Web3 Awareness Growth

2025/06/07
I Will Deliver A New Niger State –Bago
News

Low Key Sallah In Niger As Bago, Etsu Nupe Urge Peace

2025/06/07
Leadership Conference advertisement

LATEST

Ronaldo Turns Down Offers To Play At Club World Cup

Tinubu Mourns Boxing Legend Nwankpa

PICTORIAL: NAF Airstrikes Destroy Terrorists’ Hideouts, Foil Eid Attack In Borno

Ireland Deports 35 Nigerians Over Immigration Rule Violations

Bitget Hosts Blockchain Education Day To Foster Web3 Awareness Growth

Low Key Sallah In Niger As Bago, Etsu Nupe Urge Peace

Plateau Govt Engages 20,000 Youths In Agro-Industrial Chains

Benue Govt Orders Residents To Vacate Flood-Prone Areas

Nasarawa Building Renewable Energy Future Through Lithium – Commissioner

Tinubu Commiserates With Ex-Kogi West Senator Adeyemi Over Mother’s Death

© 2025 Leadership Media Group - All Rights Reserved.

No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Health
  • Entertainment
  • Opinion
    • Editorial
  • Columns
  • Football
  • Others
    • LeVogue Magazine
    • Conferences
    • National Economy
  • Contact Us

© 2025 Leadership Media Group - All Rights Reserved.